Aberdeen Group
KALA icon

Aberdeen Group’s KALA BIO KALA Stock Holding History

Aberdeen Group’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17
Closed -$420K – 904
2018
Q3 		$420K Buy
+17
New +$518K ﹤0.01% 873

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Aberdeen Group's KALA Position: Q4 2018 in Review

Aberdeen Group sold out of KALA BIO (KALA) in Q4 2018, closing a stake of 17 shares — an estimated $420K sold.

Aberdeen Group first reported a position in KALA in Q3 2018 and held it in 1 quarter. The position peaked at $420K in Q3 2018. 64 funds tracked by Wall St. Rank hold KALA as of Q4 2018.

  • Aberdeen Group reported no remaining KALA BIO position as of Q4 2018 after selling out during the quarter.
  • Aberdeen Group sold 17 KALA BIO shares in Q4 2018, an estimated $420K.
  • Aberdeen Group first reported a position in KALA BIO in Q3 2018 and held it in 1 quarter.
  • Aberdeen Group's KALA BIO position peaked at $420K in Q3 2018.
  • 64 funds tracked by Wall St. Rank held KALA BIO as of Q4 2018.

Based on Aberdeen Group's 13F filing for Q4 2018, filed 12 Feb 2019.